Observational studyBMC cancer2026

Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparative cohort study.

Fang Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.